Gentamicin is an antibiotic used to treat serious bacterial infections, particularly those caused by gram-negative bacteria. It works by binding to bacterial ribosomes and shutting down protein synthesis, which kills the bacteria rather than simply slowing their growth. Gentamicin is available as an injectable drug for systemic infections and as eye drops or ointment for eye infections.
Types of Infections Gentamicin Treats
Gentamicin targets a specific group of dangerous bacteria including Pseudomonas aeruginosa, E. coli, Klebsiella, Proteus, Serratia, and Staphylococcus species. These organisms cause some of the most difficult-to-treat hospital-acquired infections, and gentamicin remains effective against many strains that resist other antibiotics.
The FDA-approved uses for injectable gentamicin include bloodstream infections (sepsis), meningitis, urinary tract infections, pneumonia, abdominal infections including peritonitis, skin and soft tissue infections, bone infections, and burn wound infections. It is also one of the first-line treatments for suspected sepsis in newborns, where it is typically paired with a penicillin-type antibiotic to cover a broad range of bacteria.
Why Gentamicin Is Often Combined With Other Antibiotics
One of gentamicin’s most important clinical roles is as a partner drug. When combined with antibiotics that attack the bacterial cell wall (like penicillins or similar drugs), gentamicin produces a synergistic effect: the cell wall damage lets more gentamicin flood into the bacterium, making the combination far more lethal than either drug alone.
This synergy is especially important in treating endocarditis, a life-threatening infection of the heart valves. Certain bacteria that cause endocarditis, particularly enterococci, are not reliably killed by a single antibiotic. Adding gentamicin at lower doses alongside a cell wall-active drug dramatically improves bacterial killing. The same combination approach is used for serious Pseudomonas infections, where gentamicin is paired with specific penicillin-type drugs.
Eye Infections
Gentamicin also comes in ophthalmic formulations, both as eye drops and as an ointment, to treat bacterial eye infections like conjunctivitis and keratitis. For mild to moderate infections, the typical approach is one to two drops every four hours. Severe eye infections may require drops as often as every hour initially. The ointment form is applied every eight to twelve hours.
How It Works Inside the Body
Gentamicin belongs to the aminoglycoside class of antibiotics. It kills bacteria by locking onto the decoding site of the bacterial ribosome, the molecular machinery that reads genetic instructions and assembles proteins. Once gentamicin binds there, the ribosome misreads its instructions, producing defective proteins that destabilize the bacterial cell membrane and ultimately kill the cell.
This mechanism is what makes gentamicin a bactericidal antibiotic: it actively kills bacteria rather than just preventing them from multiplying. Its killing power is also concentration-dependent, meaning higher peak levels in the blood produce faster, more complete bacterial death. This property directly shapes how the drug is dosed.
How Gentamicin Is Dosed and Monitored
Gentamicin is given by injection or IV infusion, never by mouth (it is poorly absorbed from the gut). Two main dosing strategies exist. Traditional dosing splits the daily amount into two or three smaller doses. Extended-interval dosing delivers the entire daily dose at once, producing a high peak concentration followed by a drug-free period that allows the kidneys to clear the medication before the next dose.
Extended-interval dosing has become the preferred approach for most patients with normal kidney function. The high peak exploits gentamicin’s concentration-dependent killing, while the drug-free window between doses reduces accumulation in the kidneys and inner ear, the two organs most vulnerable to damage. Reaching effective blood levels quickly has been linked to better outcomes, so dosing is calculated carefully based on body weight and kidney function.
Blood levels are checked during treatment to make sure the drug reaches effective concentrations without accumulating to toxic levels. In newborns, a blood sample drawn around 22 hours after the first dose helps guide dosing intervals. For adults, both peak and trough levels are monitored, with specific targets varying by infection type. Urinary tract infections, for example, require lower peak levels than pneumonia or bloodstream infections.
Kidney and Ear Damage Risks
Gentamicin’s most significant side effects are kidney damage (nephrotoxicity) and inner ear damage (ototoxicity). These risks are the main reason the drug requires blood level monitoring and is typically used for short courses.
The kidney is vulnerable because of how it handles the drug. About 5 to 10 percent of each dose gets absorbed into the cells lining the kidney’s filtration tubes, where it can accumulate to concentrations far exceeding blood levels. This buildup damages those cells and can impair kidney function. The damage is usually reversible if caught early and the drug is stopped, but prolonged exposure or pre-existing kidney problems increase the risk of lasting harm.
Inner ear damage is the more concerning long-term risk because it is often irreversible. Gentamicin preferentially damages the vestibular system, which controls balance, rather than hearing (though hearing loss can also occur). A study of children who received gentamicin as newborns found that nearly half showed measurable vestibular abnormalities on specialized testing, even though most had no obvious symptoms of imbalance in daily life. Early signs of vestibular damage can include dizziness, a sensation that the visual world bounces during head movement, and unsteadiness. These symptoms can be subtle and easy to miss, especially in young children, where delays in motor milestones like walking or learning to ride a bike may be the only clue.
The ototoxicity risk has a genetic component. People carrying a specific mitochondrial mutation (A1555G) are hypersensitive to aminoglycoside-induced ear damage because gentamicin binds to their mitochondrial ribosomes, which structurally resemble bacterial ribosomes, more readily than in the general population. Some hospitals now offer rapid genetic screening before aminoglycoside use.
Who Should Not Receive Gentamicin
Gentamicin is contraindicated in people with myasthenia gravis, an autoimmune condition that weakens voluntary muscles. The drug can worsen muscle weakness to a dangerous degree, potentially causing respiratory failure. Patients with significant kidney impairment require dose adjustments and more frequent monitoring rather than standard dosing. Those already taking other drugs that can harm the kidneys or ears need especially close surveillance during treatment.
Use in Newborns
Gentamicin is one of the most commonly used antibiotics in neonatal intensive care units worldwide. The standard starting dose for newborns is 5 mg/kg, given intravenously. Because newborn kidneys are still maturing, the drug clears more slowly, and dosing intervals are adjusted accordingly. Babies with birth complications like oxygen deprivation at delivery, kidney problems, or those on heart-lung bypass machines require trough level checks before every dose to prevent accumulation. For uncomplicated courses lasting less than seven days, monitoring is lighter, typically just a single drug level check to confirm appropriate dosing.